What Is Tirzepatide?
Tirzepatide, also known as Tirzepatide-AEVB, is a new medication developed by the pharmaceutical company Eli Lilly and Company. It is a once-weekly injection that combines the properties of two hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones work together to control blood sugar levels and regulate food intake by signaling the brain to feel full.
Tirzepatide was initially developed as a treatment for type 2 diabetes, but recent clinical trials have shown its effectiveness in promoting weight loss as well. In a 74-week study, participants lost an average of 12.4% of their body weight with tirzepatide, and there were also improvements in metabolic markers such as blood pressure and cholesterol levels.
What Is Semaglutide?
Semaglutide is a medication developed by the pharmaceutical company Novo Nordisk. It is also a GLP-1 agonist, meaning it mimics the function of the GLP-1 hormone. Semaglutide is approved for use in treating type 2 diabetes and has recently gained FDA approval for weight loss as well.
Semaglutide is available as a once-weekly injection under the brand name Ozempic, and in a higher dose as a once-daily injection under the brand name Wegovy. In clinical trials, participants taking semaglutide for weight loss experienced an average weight loss of 15% of their body weight and also saw improvements in other metabolic markers.